Klitgaard, Henrik <br/><br/>
Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.  [electronic resource] 

 -  Epilepsia  Apr 2016 
 - 538-48 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1528-1167 
<br/><br/><label>Standard No.: </label>10.1111/epi.13340  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Anticonvulsants--metabolism<br/>Dose-Response Relationship, Drug<br/>Drug Discovery--methods<br/>Drug Evaluation, Preclinical--methods<br/>Epilepsy--drug therapy<br/>Humans<br/>Ligands<br/>Membrane Glycoproteins--metabolism<br/>Nerve Tissue Proteins--metabolism<br/>Pyrrolidinones--metabolism<br/>Treatment Outcome